Abstract: The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.

Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Abstract: An object of the present invention is to provide a method for screening for a prophylactic or therapeutic agent for tauopathy capable of blocking the propagation of tau-mediated neurodegeneration. A method for screening for a prophylactic or therapeutic agent for tauopathy, comprising the following steps (1) to (3): (1) contacting neurons having a mutant MAPT gene with a test substance; (2) measuring any one index selected from the group consisting of the following (a) to (e) in the neurons: (a) the amount of a tau oligomer in a culture supernatant.

Abstract: A liquid injection method for injecting a liquid into a culture vessel includes tilting the culture vessel around a horizontal axis at a tilt angle (X°) of greater than 0° and 50° or less, wherein adherent cells are adhered to the culture vessel; and injecting the liquid into the culture vessel at a predetermined linear velocity (Y mm/s) via a wall surface of the culture vessel tilted at the tilt angle (X°), wherein the tilt angle (X) and the linear velocity (Y) satisfy the following (formula 1): Y?5.075X+123 (formula 1).

Abstract: The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), which contains one or more kinase inhibitors selected from the group consisting of an epithelial cell growth factor receptor (EGFR) inhibitor, a fibroblast growth factor receptor (FGFR) inhibitor, an Aurorakinase inhibitor, a protein kinase A (PKA) inhibitor, a protein kinase C (PKC) inhibitor, an MEK inhibitor, an Met inhibitor, a JNK inhibitor, a Syk inhibitor and a JAK inhibitor, a prostaglandin analogue and an estrogen receptor antagonist, or one or more kinase inhibitors selected from the group consisting of Tivozanib and an analog thereof, SB 216763, Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, Sunitinib and an analog thereof, GSK-3 Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-265, Indirubin-3?-monoxime, HYDRASTINE (1R,9S), PIPERINE, BUTAMBEN, Axitinib and an analog thereof, APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and an analog

Abstract: The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.

Abstract: The present invention provides a method for producing astrocytes from neural progenitor cells, the method comprising: (1) culturing neural progenitor cells in a culture medium comprising a neurotrophic factor; (2) dissociating the cells obtained in the step (1); and (3) subjecting the cells obtained in the step (2) to adherent culture in a culture medium comprising a neurotrophic factor using an uncoated culture vessel.

Abstract: A light source control device includes a constant-current circuit that collectively supplies a current to a plurality of LEDs, a current detection circuit that divides the plurality of LEDs into groups and detects a current amount of a current supplied to each of the groups, and a microcomputer that detects an open fault in the LEDs on the basis of a ratio of the current amount in each of the groups and controls a current supplied from the constant-current circuit to be reduced in a case where an open fault is detected in the LEDs.

Abstract: The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene. A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.

Abstract: The present invention provides a method for screening a therapeutic and/or prophylactic agent for Alzheimer's disease using at least one index selected from the levels of A? oligomers, BiP, cleaved caspase 4, PRDX4 and ROS in nerve cells or the like whose differentiation has been induced from iPS cells derived from somatic cells of a patient with Alzheimer's disease.

Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Abstract: A controller determines whether parallel-connected light sources include a faulty light source. When a faulty light source is included, the controller controls at least one of a current supply unit and a switching unit such that a current is continuously supplied to normal light sources being light sources of the light sources except for the faulty light source.

Abstract: A controller determines whether parallel-connected light sources include a faulty light source. When a faulty light source is included, the controller controls at least one of a current supply unit and a switching unit such that a current is continuously supplied to normal light sources being light sources of the light sources except for the faulty light source.

Abstract: The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.

Abstract: A light source control device includes a constant-current circuit that collectively supplies a current to a plurality of LEDs, a current detection circuit that divides the plurality of LEDs into groups and detects a current amount of a current supplied to each of the groups, and a microcomputer that detects an open fault in the LEDs on the basis of a ratio of the current amount in each of the groups and controls a current supplied from the constant-current circuit to be reduced in a case where an open fault is detected in the LEDs.

Abstract: The present invention provides a method for producing astrocytes from neural progenitor cells, the method comprising: (1) culturing neural progenitor cells in a culture medium comprising a neurotrophic factor; (2) dissociating the cells obtained in the step (1); and (3) subjecting the cells obtained in the step (2) to adherent culture in a culture medium comprising a neurotrophic factor using an uncoated culture vessel.

Abstract: A normal video data acquisition section acquires, as normal video data, a plurality of pieces of video data respectively assigned to a plurality of light sources in normal display from an input video signal A computing section performs a predetermined computation on the plurality of pieces of video data included in the normal video data to generate auxiliary video data used in place of the normal video data in auxiliary display. A selection section performs, in accordance with an instruction from a control section, a selection process for providing any one of the normal video data and the auxiliary video data to a modulation driving section.

Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Abstract: A microcomputer of a light source control device specifies an LED belonging to LEDs and subjected to a short-circuit failure based on a result of determination by a short-circuit failure detecting circuit and current amounts sensed by current sensing circuits respectively. The microcomputer makes corresponding one of switching elements interrupt supply of a current to the specified LED. The microcomputer makes a constant current circuit supply an LED not specified with a current not exceeding a current responsive to the number of such LEDs not specified.

Abstract: The present invention provides a method for detecting onset of, or the risk of development of, a protein misfolding disease, and a method for predicting the age of onset of a protein misfolding disease using nerve cells derived from iPS cells. The present invention also provides a kit to be used in these methods.